Navigation Links
Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Novel Agents for Cancer Diagnosis and Targeted Therapy
Date:10/28/2013

Gilbertsville, PA (PRWEB) October 28, 2013

Rockland Immunochemicals Inc. today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute, National Institutes of Health (NCI/NIH) to develop nanoprobes for in vivo imaging of cancer cells and tumors that express one of the three important cancer therapeutic targets: EGFR, Her2 and Mesothelin. This project is a joint collaboration between Rockland and Abzyme Therapeutics with in vivo imaging consultants from Yale University and the University of Pittsburgh.

Medical imaging is a key component in the clinical management of cancer patients. Cancer imaging agents are used in conjunction with medical imaging equipment and, by highlighting the contrast between normal and malignant tissues, allow the collection of information on cancer presence and progression. Developing novel imaging agents that can be used for imaging and targeted radiotherapy of cancer would greatly enhance the efficacy of the cancer patient management and help usher in a new era of personalized cancer therapy.

According to market research firm Markets and Markets, the global diagnostic imaging market, which stood at $20.7 billion in 2010, is expected to swell to $26.6 billion by 2016. This expected rise is attributed to an aging population, increasing awareness about preventive care, and advancements in the field.

In Phase 1, Rockland and Abzyme Therapeutics will develop, label, and characterize high-affinity single domain antibodies (sdAbs) against EGFR, Her2 and Mesothelin. Under the terms of this grant, Abzyme Therapeutics will develop single domain antibodies and Rockland will be responsible for bioconjugation and in vivo characterization.

“Despite significant scientific progress, very few cancer imaging agents are available in the clinic,” commented Carl A Ascoli, PhD, Laboratory Director at Rockland Immunochemicals. “The size, ease of manufacture, and condition-resistant nature of sdAbs make them the best choice as capture molecules. We expect that our sdAb imaging agents will have superiority over other agents designed for in vivo and in situ biodetection and diagnosis.”

“In these times of shrinking government investment in research, this SBIR grant validates Rockland’s business model of collaboration with leading academic institutions to aggregate, develop and commercialize technologies that will ultimately benefit humanity,” continued Jim Fendrick, President and CEO of Rockland Immunochemicals. “This research is in line with the company’s expertise in antibodies and antibody based tools. We are confident that this collaboration will generate significant innovation and that the results will have great scientific and commercial applications.”

In the planned Phase II portion of this project, the key antibodies will be radionuclide labeled and characterized using PET scanners in collaboration with Yale University and University of Pittsburg. Radionuclide labeled antibodies specific to cancer cells can be used not only as in vivo imaging agents but also for targeted cancer therapy.

About Rockland Immunochemicals
Rockland Immunochemicals has supported the academic, biopharma and diagnostic industries with antibodies and antibody based tools™ for basic research, assay development and preclinical studies for over 50 years. With facilities in Pennsylvania, Rockland manufactures over 10,000 products ideally suited for integration into critical assays such as western blotting, immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA and FLOW cytometry. Additional information about Rockland Immunochemicals’ Life Science Tools and services can be found on the company’s website at http://www.rockland-inc.com.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11271069.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. $9 million grant awarded to UH to study, treat learning disabilities
3. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
4. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
5. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
6. Southeast program to fight diabetes awarded nearly $10 million by HHS
7. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
8. 29 Johns Hopkins stem cell researchers awarded funding
9. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
10. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
11. EMBO Gold Medal 2012 awarded to Jiri Friml
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental team ... patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain ... the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton ...
(Date:3/29/2017)... ... 2017 , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, ... with or without a referral. Dr. Cotey knows that interceptive orthodontics in ... When patients receive early treatment, they may achieve straight teeth with less treatment in ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... ... HealthCareMandA.com will host an important webinar — Home Health & Hospice: Buying, Selling ... the webinar will also be made available following its live presentation. The webinar is ... popular targets for healthcare investors. This highly fragmented sector bounced back in 2016, as ...
(Date:3/29/2017)... ... ... Hamlin Dental Group, multi-location dental office in North Hollywood , Van ... safe and effective options, and can be used alone or in conjunction with other ... care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as well, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 Wound care ... promote healing of the wound. The industry mainly consists ... products for the treatment of wounds caused by mechanical, ... due to diseases such as diabetes, skin related diseases, ... Europe was the largest region in ...
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research ... Chromatograph Market 2017-2021" report to their offering. ... The global gas chromatograph market ... The report, Global Gas Chromatograph Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/29/2017)... 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused company ... announced that Carmine N. Stengone , president and chief executive ... & Company 16 th Annual Healthcare Conference on Wednesday, April ... Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology: